MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
详细信息 查看全文
- 作者：Peter J.R. Ebert1 ; Jeanne Cheung1 ; Yagai Yang1 ; Erin McNamara1 ; Rebecca Hong1 ; Marina Moskalenko1 ; Stephen E. Gould1 ; Heather Maecker1 ; 2 ; Bryan A. Irving1 ; 3 ; Jeong M. Kim1 ; Marcia Belvin1 ; Ira Mellman1 ; mellman.ira@gene.com" class="auth_mail" title="E-mail the corresponding author
- 刊名：Immunity
- 出版年：2016
- 出版时间：15 March 2016
- 年：2016
- 卷：44
- 期：3
- 页码：609-621
- 全文大小：3834 K
文摘
- •
Pharmacologic inhibition of MEK potentiates rather than hinders anti-tumor T cells
- •
MEK inhibitors nonetheless suppress anti-tumor priming in lymph nodes in vivo
- •
MEK inhibitors potentiate anti-tumor T cells by impairing TCR-driven apoptosis
- •
MEK inhibition combines with anti-PD-L1 treatment to yield durable tumor regression